Patents Assigned to Gene Targeting Corp.
  • Tissue specific adenovirus vectors for breast cancer treatment
    Patent number: 6096718
    Abstract: Replication defective adenoviral vectors serve as vehicles for genes encoding products that kill cells in which the genes are transferred and activated. The novel vectors include tissue specific promoters, and are successful in targeting mammalian cancer cells, in particular human breast cancer cells, and causing tumors to regress.
    Type: Grant
    Filed: June 5, 1997
    Date of Patent: August 1, 2000
    Assignee: Gene Targeting Corp.
    Inventors: Sigmund Weitzman, Bayar Thimmapaya, Leonard Anderson